Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.

11/11/2026, 3:00 PM • The Motley Fool

Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.

11/11/2026, 1:00 PM • GlobeNewswire

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

11/10/2026, 11:00 AM • GlobeNewswire

PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology

PsiThera, a biotechnology company developing oral drugs for immune and inflammatory diseases, announced the closing of a $25 million financing round. New investors AbbVie Ventures and Lumination Capital joined existing investors Samsara BioCapital and Lightstone Ventures. The funding will support development of the company's lead oral TNFα inhibitor and advancement of its TL1A program, leveraging PsiThera's proprietary QUAISAR platform that combines physics-based simulation and machine learning.

11/10/2026, 7:00 AM • GlobeNewswire

The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?

Invesco Pharmaceuticals ETF (PJP) delivers higher returns (32.8% over one year, 10.7% CAGR since 2021) with concentrated U.S. pharma exposure but higher fees (0.58%), while iShares Global Healthcare ETF (IXJ) offers broader global diversification across 109 holdings, lower costs (0.38%), and higher dividend yield (1.3%), making it suitable for cost-conscious investors seeking diversified healthcare exposure.

11/07/2026, 9:15 AM • The Motley Fool

Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

Genmab announced that 22 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, will be presented at the 2026 ASH Annual Meeting in December. Highlights include first presentation of Phase 3 EPCORE DLBCL-4 study results showing epcoritamab plus lenalidomide in relapsed/refractory DLBCL, along with updated data from multiple trials across B-cell malignancies demonstrating the drug's versatility as monotherapy and in combinations.

11/04/2026, 9:00 AM • GlobeNewswire

Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026

Nxera Pharma has revised its 2026 financial forecast upward following an exclusive global license agreement with AbbVie for its EP4 agonist program NXE0033744. Nxera will receive a US$100 million upfront payment, expected to be recognized in Q4 2026, along with potential milestone payments up to US$1.37 billion and tiered royalties. The revised forecast now projects revenue of JPY48.8 billion, core operating profit of JPY22.8 billion, and operating profit of JPY15.7 billion for 2026.

11/04/2026, 3:44 AM • GlobeNewswire

The Best Dividend Stocks to Buy With $5,000 in November

The article recommends three dividend stocks as attractive buying opportunities in November: AbbVie, Johnson & Johnson, and Medtronic. Despite pressure from higher-growth AI stocks and rising Treasury yields, these Dividend Kings offer solid long-term value with strong cash flow generation and room for future dividend increases. AbbVie benefits from successful drug launches offsetting Humira losses, J&J's streamlined business shows steady growth, and Medtronic's turnaround from past challenges presents a bargain valuation.

11/02/2026, 12:15 PM • The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie and Bristol Myers Squibb represent contrasting investment strategies in pharmaceuticals. AbbVie offers faster growth with strong immunology drugs (Skyrizi, Rinvoq) and expanding pipeline, trading at premium valuations with expected net income growth to $14.6B. Bristol Myers Squibb trades at significantly lower multiples with stable oncology/hematology focus but faces a harder recovery timeline. The article recommends AbbVie for investors seeking immediate growth prospects despite higher valuations.

11/02/2026, 11:00 AM • The Motley Fool

Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo

AbbVie's experimental drug ABBV-466, combining Skyrizi with trosunilimab, showed promising Phase 2 results for Crohn's disease, nearly doubling remission rates compared to either drug alone. Analysts view it as a potential blockbuster follow-up to Skyrizi, though Phase 3 trials and regulatory approval still lie ahead. The company's strong track record in lifecycle management supports investor confidence.

11/02/2026, 5:25 AM • The Motley Fool

Better Dividend ETF: iShares HDV's High Yields vs. ProShares NOBL's Dividend Growth

The article compares two dividend-focused ETFs: iShares Core High Dividend ETF (HDV) and ProShares S&P 500 Dividend Aristocrats ETF (NOBL). HDV offers a lower expense ratio (0.08% vs 0.35%), higher dividend yield (3.2% vs 2.0%), and superior 1-year returns (17.86% vs 7.28%), making it the author's preferred choice. NOBL focuses on companies with 25+ years of consecutive dividend increases, offering greater stability but at higher costs.

10/31/2026, 2:58 PM • The Motley Fool

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

10/28/2026, 1:00 PM • GlobeNewswire

Arcutis Appoints Rob Scott, MD to Board of Directors

Arcutis Biotherapeutics announced the appointment of Dr. Rob Scott, a veteran pharma executive with over 40 years of experience, to its Board of Directors effective October 23, 2026. Dr. Scott, formerly Chief Medical Officer at AbbVie, brings extensive expertise in drug development and regulatory approvals. The company highlighted strong adoption of its ZORYVE product and a growing pipeline of new indications and novel biologics.

10/28/2026, 9:00 AM • GlobeNewswire

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

10/26/2026, 1:00 PM • GlobeNewswire

Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT?

iShares Global Healthcare ETF (IXJ) and First Trust NYSE Arca Biotechnology Index Fund (FBT) offer different approaches to healthcare investing. IXJ provides diversified global exposure across 109 holdings with a lower 0.38% expense ratio and 1.4% dividend yield, making it suitable for long-term investors. FBT concentrates on 30 biotech companies with higher volatility but delivered 43.8% returns over one year versus IXJ's 19.5%. For most investors, IXJ's lower costs and stability make it the better foundation, while FBT suits those with higher conviction in biotech's continued growth.

10/26/2026, 8:10 AM • The Motley Fool